{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P15692",
      "entity_text" : "VEGF",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:25102846",
      "entity_text" : "XL-184",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Targeting these pathways has shown some promise--cabozantinib (XL-184) inhibits tyrosine kinases of c-Met and VEGF, and in phase II clinical trial, demonstrated significant benefit specifically for CRPC patients with bone metastases; However, it did not reach its primary endpoint (bone pain alleviation) in phase III trial, with no significant difference in bone pain alleviation between the treatment and control (mitoxantrone / prednisone) arms.",
  "reading_complete" : "2020-08-04T13:31:44Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T13:29:20Z",
  "trigger" : "inhibits",
  "evidence" : [ "XL-184) inhibits tyrosine kinases of c-Met and VEGF" ],
  "pmc_id" : "4708226",
  "score" : 0
}